

## Monthly Market Commentary

Most global equity indices finished the month broadly unchanged but the point-to-point differences disguised a volatile month which saw sell-offs, recoveries and a pronounced rotation in leadership.

In our recent September quarterly report, we drew attention to the highly unusual discount at which stable or defensive stocks were trading versus the market. This has, to some extent, reversed with profit taking, monetary policy uncertainty, and some weak economic updates (softer labour trends, weaker consumer confidence) driving selling in cyclical and growth stocks.

Concerns around the AI complex also contributed to the rotation, namely the ecosystem's growing circularity, eye-watering capex, and aggressive multiples. Not even strong earnings from NVIDIA (Q3 sales +62%) could turn the tide, with shares in the AI poster child down 12.6% for the month. Other notable laggards in the area included Microsoft and Amazon with shares down 5.0% and 4.5%, respectively.

Against this backdrop, the NASDAQ broke its seven-month streak of gains, finishing down 1.5%, while the S&P500 barely delivered performance, eking out a 0.13% gain. In contrast, small caps were notably stronger with the S&P600 Small Cap Index rising 2.5% in November. Breadth also improved with the S&P500 Equal Weighted Index rising 1.7%.

In Europe, political and fiscal concerns weighed on both sides of the English Channel with France's CAC40 and the UK's FTSE flat for the month in local currencies. Germany's DAX closed modestly lower, down 0.5% in local currencies. Reversing some of last month's stellar gains, Japan's Nikkei225 closed down 4.1% with profit taking and AI crosswinds contributing to selling pressure. Elsewhere in Asia, China's Shanghai Composite Index was also weaker, finishing down 1.7% for the month.

November saw notable dispersion within sectors. Information Technology was the biggest laggard, falling 4.5%, along with Industrials and Consumer Discretionary which fell 1.6% and 1.7%, respectively.

Health Care was the standout, rising 8% with fellow defensive sectors, Utilities and Staples also delivering good performance, up 2% and 3.8%, respectively.

Communications was another source of performance, up 4.2%, aided by strong gains in search giant, Alphabet after Berkshire Hathaway disclosed a new position in the Google parent. Commodity price strength aided Materials, which also delivered solid performance for the month, up 4%.

Against this backdrop, the Fund returned 2.50% for the month.

The AUD fell 0.1% against the USD, while commodities were stronger. The Bloomberg Commodity Index rose 2.9%, as strength in precious metals more than offset weakness in oil with WTI falling 4%. VIX also fell 1 point to 16.35 while yields on 10yr US Treasuries were lower by 6bps to close at 4.01%.

Pharmaceutical giant, Roche was the biggest contributor to Fund performance in November with shares benefitting from positive drug trial updates and the broader rally in Health Care. Medical technology group, Medtronic was the second largest contributor with its stock up strongly following a solid Q2 result where management raised FY26 guidance. French-based rewards group, Pluxee was the biggest detractor during the month with shares falling on the back of adverse regulatory announcements in Brazil.

In terms of new positions during the month, the Fund gained exposure to AO Smith, the largest water heater manufacturer in the US. In addition to attractive industry dynamics, the top three players have more than a 90% share, AO Smith has a history of generating strong cash flows alongside high returns of around 35% ROIC with a net cash balance sheet. With the recent de-rating largely driven by weakness in the new housing market, we think the stock now offers good value with potential share price outcomes in the mid-\$80s over the next few years, approximately 25% upside.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

## Performance as at 30 November 2025<sup>1</sup>

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) <sup>2</sup>
Total Return <sup>3</sup>	2.50%	1.61%	3.06%	9.55%	8.88%	10.59%	9.26%	7.68%	7.45%
Avg. Market Exposure <sup>4</sup>	57%	58%	59%	62%	60%	58%	58%	59%	61%

<sup>1</sup> Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.  
<sup>2</sup> Inception date for performance calculation is 18 August 2008.  
<sup>3</sup> Past performance is not a reliable indicator of future performance.


<sup>4</sup> Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008.

## Growth of \$10,000 Since Inception<sup>5</sup>



<sup>5</sup> Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions. Past performance is not a reliable indicator of future performance.

## Annual Distributions<sup>6</sup>




<sup>6</sup> Illustrates Distribution Returns for the Talaria Global Equity Fund Complex ETF Units for the financial year ending 30 June 2025. Inception date is 18 August 2008.

Top 10 Holdings<sup>7</sup>

Company Name	Holding	Country	Sector	Description
Newmont	6.2%	USA	Materials	One of the top 3 gold producers in the world
EOG Resources	4.8%	USA	Energy	One of North America's largest independent oil and gas producers
Roche	4.5%	Switzerland	Health Care	A global leader in cancer treatments
CF Industries	4.2%	USA	Materials	North America's largest manufacturer of nitrogen-based fertiliser
Bunzl	4.2%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Everest Group	4.1%	USA	Financials	Leading global provider of reinsurance and insurance services
Essity	4.1%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden
Chubb	4.0%	USA	Financials	Global property & casualty insurance company
Johnson & Johnson	3.8%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company
HP	3.6%	USA	Information Technology	One of the world's largest makers of personal computers and printing equipment


<sup>7</sup> Weightings include equity held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation<sup>8</sup>



<sup>8,9</sup> Weightings include equity held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation<sup>9</sup>



\* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

APIR Code	AUS0035AU	Inception Date	18 August 2008
Management Fee	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$4.95130 (30 Nov 2025)
Major Platform Availability	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconiQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Buy / Sell Spread	0.20% / 0.20%
		Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Complex ETF's Target Market Determination is available [here](#). A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned November 2024 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](#) for ratings information and to access the full report. © 2025 Lonsec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 15 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit [Geniumip.com.au](#) for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

